NASDAQ:SRRA Sierra Oncology (SRRA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free SRRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$54.99▼$54.9950-Day Range$54.73▼$54.9952-Week Range$14.91▼$55.19VolumeN/AAverage Volume931,731 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sierra Oncology alerts: Email Address Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Sierra Oncology Stock (NASDAQ:SRRA)Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Read More Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one SRRA Stock News HeadlinesFebruary 21, 2024 | thestreet.comSierra Oncology Inc.November 9, 2023 | time.comSierra Coupon for OctoberMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.September 18, 2023 | msn.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaJune 16, 2023 | proactiveinvestors.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 12, 2023 | fool.comSierra Oncology (NASDAQ: SRRA)March 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 25, 2023 | benzinga.comCelyad Oncology Stock (NASDAQ:CYAD), Quotes and News SummaryFebruary 22, 2023 | bbc.co.ukSierra LeoneJanuary 20, 2023 | finance.yahoo.comInterventional Oncology Global Market - Forecast To 2029January 5, 2023 | nasdaq.comGSK Signs Deal to Develop Antibodies for Treating CancerOctober 12, 2022 | marketwatch.comSareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares FallSeptember 25, 2022 | marketwatch.comCompanion Diagnostic Tests in Oncology Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2027September 1, 2022 | thestreet.com15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesAugust 8, 2022 | yahoo.comSierra Leone passes new laws to boost landowners' rightsJuly 4, 2022 | marketwatch.comSareum Holdings Says GSK Completes Acquisition of Sierra OncologyJune 17, 2022 | finance.yahoo.comSierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug AdministrationJune 13, 2022 | uk.finance.yahoo.comSierra Oncology hits 52w high – but will it continue?May 26, 2022 | finance.yahoo.comMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual MeetingMay 12, 2022 | finance.yahoo.comSierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual MeetingMay 6, 2022 | finance.yahoo.comSierra Oncology Reports First Quarter 2022 ResultsMay 2, 2022 | stockhouse.comSIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRAApril 14, 2022 | msn.comBiotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & MoreApril 14, 2022 | msn.comAnalyzing Sierra Oncology Inc's Short InterestApril 14, 2022 | markets.businessinsider.comAnalyst Ratings for Sierra OncologySee More Headlines Receive SRRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone(604) 558-6536FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.88% Return on Assets-100.01% Debt Debt-to-Equity Ratio0.02 Current Ratio21.27 Quick Ratio21.27 Sales & Book Value Annual Sales$300,000.00 Price / Sales4,476.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book8.93Miscellaneous Outstanding Shares24,419,000Free Float13,650,000Market Cap$1.34 billion OptionableOptionable Beta0.03 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Stephen George Dilly M.B.B.S (Age 62)Pres, CEO & Director Comp: $1.02MMr. Sukhi Jagpal CPA (Age 48)CA, CBV, CPA, M.B.A., MBA, Chief Financial Officer Comp: $648.02kDr. Barbara J. Klencke M.D. (Age 65)Chief Medical Officer Comp: $773.39kMs. Christina Thomson J.D. (Age 51)M.S., Gen. Counsel, Chief Compliance Officer & Sec. Mr. William D. Turner (Age 56)Chief Regulatory & Technical Operations Officer Mr. Kevin Norrett M.B.A. (Age 49)M.S., Chief Bus. Officer More ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLProthenaNASDAQ:PRTADay One BiopharmaceuticalsNASDAQ:DAWNMannKindNASDAQ:MNKDPacira BioSciencesNASDAQ:PCRXView All Competitors SRRA Stock Analysis - Frequently Asked Questions How were Sierra Oncology's earnings last quarter? Sierra Oncology, Inc. (NASDAQ:SRRA) announced its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.78) by $0.32. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Co-Diagnostics (CODX), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and Biocept (BIOC). This page (NASDAQ:SRRA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.